medigraphic.com
ISSN 0188-2198 (Print)

2017, Number 4

<< Back Next >>

Rev Mex Cardiol 2017; 28 (4)

Cardiac senile amyloidosis: a review

Harrison GC, Harrison RD, Sánchez LF, Guerrero GH, Domínguez CLG

Language: English
References: 58
Page: 180-188
PDF size: 295.80 Kb.


ABSTRACT

Cardiac senile amyloidosis related to wild-type transthyretin is not so infrequent as previously thought, several cases of heart failure with preserved ejection fraction might be related to this infiltrative disorder. Usually it is underdiagnosed because of the requirement of histological diagnosis and reluctance to do biopsy in this frail elderly population. Noninvasive diagnostic methods available will increase diagnosis of cardiac transthyretin amyloidosis (ATTR), and the direct consequence will be more investigations and clinical trials on diagnosis and therapeutics of ATTR.


REFERENCES

  1. Falk RH. Cardiac amyloidosis: a treatable dissease, often overlooked. Circulation. 2011; 124 (9): 1079-1085.

  2. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A4, Grogan DR5, Dunlay SM et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fall. 2014; 2 (2): 113-122.

  3. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36 (38): 2585-2594.

  4. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol. 2000; 130 (2-3): 88-98.

  5. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M et al. Diagnosis, prognosis and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015; 66 (21): 2451-2466.

  6. Maurer MS, Elliot P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis of caridad amyloidosis. Circulation. 2017; 135 (14): 1357-1377.

  7. Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distributionn of senile cardiovascular amyloid: a clinicopathological correlation. Am J Med. 1983; 75 (4): 618-623.

  8. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008; 40 (3): 232-239.

  9. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016; 387 (10038): 2641-2654.

  10. Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin light-chain amylodosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016; 135 (3): 172-190.

  11. Galat A, Guellich A, Bodez D, Slama M, Dijos M, Zeitoun DM et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J. 2016; 37 (47): 3525-3531.

  12. Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015; 128 (12): 1275-1280.

  13. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003; 10 (3): 160-184.

  14. Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011; 42 (11): 1785-1791.

  15. Cappelli F, Baldasseroni S, Bergesio F, Perlini S, Salinaro F, Padeletti L et al. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis. Clin Cardiol. 2015; 38 (2): 69-75.

  16. Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular disease: cardiomyopathies that look alike. J Am Coll Cardiol. 2010; 55 (17): 1769-1779.

  17. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013; 34 (7): 520-528.

  18. Granstam SO, Rosengren S, Vedin O, Kero T, Sörensen J, Carlson K et al. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catherization. Amyloid. 2013; 20 (1): 27-33.

  19. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS. Magnetic resonance in transthyretin caridad amyloidosis. J Am Coll Cardiol. 2017; 70 (4): 466-477.

  20. Rapezzi C, Tinuper AL, Lorenzini M. Broadening the phenotypic spectrum and the diagnostico needs of TTR-related caridad amyloidosis. J Am Coll Cardiol. 2017; 70 (4): 478-480.

  21. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014; 7 (2): 133-142.

  22. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009; 54 (15): 1407-1424.

  23. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al. Prognostic value ofate gadolinium enhancement cardiovascular magnetice resonance in cardiac amyloidosis. Circulation. 2015; 132 (16): 1570-1579.

  24. Karamitsos TD, Piecnick SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM et al. Non contrast T1 mapping for the diagnosis of cardiac amyloidosis. J Am Coll Cardiol Img. 2013; 6 (4): 488-497.

  25. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK et al. Native T1 mapping in transthyretin amyloidosis. JACC Imaging. 2014; 7 (2): 157-165.

  26. Barison A, Masci PG, Aquaro GD. CMR-Based characterization of cardiac amyloidosis. J Am Coll Cardiol. 2014; 7 (10): 1067-1068.

  27. Falk RH, Lee VW, Rubinow A, , Hood WB Jr, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983; 51 (5): 826-830.

  28. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99m-Tc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46 (6): 1076-1084.

  29. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O et al. Usefulness and limitaciones of 99m-Tc-3,3-diphosphono-1,2-propanodicarboxylic acid sicintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011; 38 (3): 470-478.

  30. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O et al. Role of (99m) Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Imaging. 2011; 4 (6): 659-670.

  31. Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL et al. Can 99m Tc-Pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Imaging. 2017; 10 (6): 708-714.

  32. Arbustini E, Merlini G. Early identification of transthyretin-related hereditary cardiac amyloidosis. JACC Imaging. 2014; 7 (5): 511-514.

  33. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013; 6 (2): 195-201.

  34. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133: 2404-2412.

  35. Minutoli F, Di Bella G, Mazzeo A, Donato R, Russo M, Scribano E et al. Comparison between 99m-Tc diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol. 2013; 200 (3): W256-W265.

  36. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009; 120 (13): 1203-1212.

  37. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996; 101 (4): 395-400.

  38. Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015; 20 (2): 155-162.

  39. Kristen AV, Scherzer K, Buss S, Aus dem Siepen F, Haufe S, Bauer R et al., Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Imaging. 2014; 7 (5): 502-510.

  40. Cassidy JT. Cardiac amyloidosis. Two cases with digitalis sensitivity. Ann Intern Med. 1961; 55: 989-994.

  41. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981; 63 (6): 1285-1288.

  42. Selvanayagam JB, Hawkins PN, Pual B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007; 50 (22): 2101-2110.

  43. Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012; 101 (10): 805-813.

  44. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006; 13 (4): 236-249.

  45. Tojo K, Sekijima Y, Kelly JW, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006; 56 (4): 441-449.

  46. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012; 18 (6): 315-319.

  47. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310 (24): 2658-2667.

  48. Takahashi R, Ono K, Shibata S, Nakamura K, Komatsu J, Ikeda Y et al. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area. J Neurol Sci 2014; 345 (1-2): 231-235.

  49. Cardoso I, Merlini G, Saraiva MJ. 4’-iodo-4’-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrills in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003; 17 (8): 803-809.

  50. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010; 8: 74.

  51. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012; 19 (Suppl 1): 34-36.

  52. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012; 421 (2-3): 185-203.

  53. Coelho T, Maia LF, da Silva AM, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P et al. Tafamidis for transthyretin familial amyloid polyneuropathy a randomized, controlled trial. Neurology. 2012; 79 (8): 785-792.

  54. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013; 260 (11): 2802-2814.

  55. Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013; 6 (6): 1011-1020.

  56. Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D et al. French Network for FAP (CORNAMYL) Effect on disability an safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013; 20 (12): 1539-1545.

  57. Scott LJ. Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs. 2014; 74 (12): 1371-1378.

  58. Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015; 8 (3): 519-526.




2020     |     www.medigraphic.com